K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.
Miller
Michael D
MD
Margot
Nicolas
N
McColl
Damian
D
Cheng
Andrew K
AK
D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019380:Anti-HIV Agents / Q000494:pharmacology*; D023241:Antiretroviral Therapy, Highly Active; D024882:Drug Resistance, Viral / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009154:Mutation; D063065:Organophosphonates / Q000494:pharmacology*; D000068698:Tenofovir; D017211:Treatment Failure
D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine